Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that have significantly improved the prognosis of various cancers, both in (neo)adjuvant and metastatic settings. Unlike other conventional therapies, ICIs elicit antitumor effects by enhancing host immune systems...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Sean, Day, Daphne, Nicholls, Stephen J., Segelov, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830229/
https://www.ncbi.nlm.nih.gov/pubmed/36636451
http://dx.doi.org/10.1016/j.jaccao.2022.09.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830229/
https://www.ncbi.nlm.nih.gov/pubmed/36636451
http://dx.doi.org/10.1016/j.jaccao.2022.09.004

Ejemplares similares